Overview

Affibody is advancing a new generation of radioligand therapies (RLTs) with precision targeting that can be applied to a broad range of cancers. Our pipeline of RLTs for major cancer types with unmet needs is based on scientific expertise that combines decades of work in discovery of  Affibody^® molecules and a deep understanding of the RLT space.

Affibody^® molecules were first described in a seminal publication in Nature Biotechnology in 1997, and since then, we have continued to expand our  Affibody^® platform, manufacturing capabilities, and clinical experience. Our long-standing collaboration with Uppsala University provides unique access to world-class RLT laboratories, animal facilities, and radiochemistry expertise, resulting in more than 1,000 publications on the  Affibody^® platform including 400 publications on its use in radiopharmaceuticals.

Our team comprises multidisciplinary experts with decades of experience building companies and advancing complex drugs through every stage of clinical development. We are guided by our core values—caring, ambitious, and goal-oriented—and we actively foster these principles across our organization as we drive toward bringing innovative medicines to patients.